Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Author Archives: PharmAust

PharmAust secures core China patent

News & Announcements 2017By PharmAustMay 5, 2017

170505_PharmAust secures core China patent

PharmAust Broker Roadshow Presentation – April 2015

News & Announcements 2015By PharmAustApril 17, 2017

150401_PharmAust Broker Roadshow Presentation – April 2015

Appendix 4C – Quarterly Report & Company Update for the period ended 31 March 2017

Financial Reports 2017, News & Announcements 2017By PharmAustApril 13, 2017

170413_Appendix 4C – Quarterly Report & Company Update for the period ended 31 March 2017

test photo album

test 1By PharmAustMarch 23, 2017Leave a comment

Top 10 Spec Stocks 2017

Research Notes 2017By PharmAustMarch 20, 2017

170320_Top 13 Speculative Stocks March 2017

Dr Richard Mollard appointed as Chief Scientific Officer of PharmAust

News & Announcements 2017By PharmAustMarch 8, 2017

170308_Dr Richard Mollard appointed as Chief Scientific Officer of PharmAust

PharmAust raises a further $534K

News & Announcements 2017By PharmAustMarch 3, 2017

170303_PHARMAUST RAISES A FURTHER $534k

Dr Richard Hopkins Appointed as CEO of PharmAust

News & Announcements 2017By PharmAustMarch 1, 2017

170301_Dr Richard Hopkins Appointed as CEO of PharmAust

PharmAust subsidiary Epichem posts record revenue in January

Articles In The NewsBy PharmAustFebruary 8, 2017

Appendix 4C – Quarterly Report & Company Update for the period ended 31 December 2016

Financial Reports 2017, News & Announcements 2017By PharmAustJanuary 31, 2017

170131_Appendix 4C – Quarterly Report & Company Update for the period ended 31 December 2016

←1
2345678910111213141516171819202122232425262728293031323334
…3536373839…
4041424344454647
48→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube
TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
Retweet on Twitter PharmAust Retweeted
pharmaust PharmAust @pharmaust ·
21h

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 5 Like on Twitter 1641272193236758529 14 Twitter 1641272193236758529
pharmaust PharmAust @pharmaust ·
1h

MND trial completes enrolment of 'Cohort 2' and prepares for interim analysis
Via @BiotechDispatch
https://biotechdispatch.com.au/news/mnd-trial-completes-enrolment-of-cohort-2-and-prepares-for-inter

Reply on Twitter 1641571161678151680 Retweet on Twitter 1641571161678151680 1 Like on Twitter 1641571161678151680 4 Twitter 1641571161678151680
pharmaust PharmAust @pharmaust ·
17h

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 2 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360
Load More
Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top